Skip to main content

Table 2 Clinical characteristics of GBM splicing types

From: Classification of glioma based on prognostic alternative splicing

  ST1(n = 49) ST2(n = 49) ST3(n = 56) Total(n = 154)
Clinical
 Age
  Median 62.8 60.1 61.0 60.24
  No. ≤ 40 years old 1 5 6 12
Survival (in months)
 Median (CI) 9.0 (5.47, 12.8) 15.1 (13.5, 17.7) 15.6 (13.5–25.5) 13.8 (12.1–15.3)
Disease-free survival (in months)
 Median (CI) 8.4 (6.0, NA) 8.5 (6.7 13.1) 11 (5.9, NA) 8.5 (6.7, 13)
Karnofsky score
 100 2 2 7 11
 90 0 2 0 2
 70–80 19 25 19 63
  < 70 8 6 16 30
Sex
 Female 18 20 16 54
 Male 31 29 40 100
Molecular
 IDH Status
  Mutant 0 3 7 10
  WT 46 45 49 140
 MGMT Promoter
  Methylated 11 17 24 52
  Unmethylated 26 24 21 71
 G-CIMP Methylation
  G-CIMP 0 2 6 8
  Non-G-CIMP 48 46 50 144
 TERT Promoter
  Mutant 4 9 12 25
  WT 45 39 41 4
 TERT Expression
  Expressed 38 42 47 127
  Not.expressed 10 7 9 26
 CHR7 Gain CHR10 loss
  Gain chr7&loss chr10 31 32 34 97
  No combined CNA 18 13 20 51
 CHR19/20 co gain
  Gain chr19/20 2 5 12 19
  No chr19/20 gain 47 40 42 129
Clusters
 Transcriptome Cluster
  CL 49 26 7 1
  MC 66 16 8 6
  NE 5 1 19 9
  PN 18 3 72 61
 Original Cluster
  Classical 39 0 0 0
  G-CIMP 7 0 1 0
 IDHmut-codel 0 1 23 20
  IDHmut-non-codel 0 4 127 67
  IDHwt 0 49 21 6
  Mesenchymal 50 0 0 0
  Neural 26 0 0 0
  Proneural 29 0 0 0
 Pan-Glioma RNA Expression Cluster
  LGr1 20 4 25 17
  LGr2 3 0 0 2
  LGr3 9 4 127 68
  LGr4 121 46 20 6
 Pan-Glioma DNA Methylation Cluster
  LGm1 7 4 18 11
  LGm2 1 0 120 59
  LGm3 0 1 14 19
  LGm4 43 14 4 0
  LGm5 59 30 12 0
  LGm6 12 5 5 5